1708 completed, 573 terminated, 470 recruiting, 344 unknown. 3655 Phase 2, 1031 Phase 1, 131 Phase 3.
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2027-01-30 | 2026-11-05 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2027-01-15 | 2026-11-09 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia CAV - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | University of Rochester | 24 | 2026-12-31 | 2026-10-16 |
Showing 20 of 3655. Sign in to see all of them.
Leukemia, Myeloid, Acute (1554) · Leukemia, Lymphocytic, Chronic, B-Cell (920) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (899) · Myelodysplastic Syndromes (718) · Lymphoma (472) · Lymphoma, Non-Hodgkin (438) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (404) · Lymphoma, Follicular (326) · Lymphoma, Mantle-Cell (297) · Lymphoma, Large B-Cell, Diffuse (293) · Burkitt Lymphoma (289) · Recurrence (280) · Hodgkin Disease (267) · Lymphoma, B-Cell, Marginal Zone (267)
Hemic and Lymphatic Diseases (3655) · Neoplasms by Histologic Type (3645) · Hematologic Diseases (3608) · Neoplasms (3538) · Immune System Diseases (2037) · Immunoproliferative Disorders (1997) · Leukemia, Myeloid (1986) · Lymphoproliferative Disorders (1975) · Lymphatic Diseases (1968) · Pathological Conditions, Signs and Symptoms (1776) · Pathologic Processes (1764) · Leukemia, Lymphoid (1742) · Disease Attributes (1700) · Chronic Disease (1527)
Cyclophosphamide (507) · Cytarabine (480) · fludarabine phosphate (295) · venetoclax (291) · Azacitidine (272) · fludarabine (262) · Rituximab (258) · Methotrexate (244) · Busulfan (196) · Filgrastim (189) · Peripheral Blood Stem Cell Transplantation (179) · Etoposide (171) · Dexamethasone (155) · Mycophenolic Acid (154) · Whole-Body Irradiation (153)
M.D. Anderson Cancer Center (347) · National Cancer Institute (NCI) (186) · Fred Hutchinson Cancer Center (134) · Memorial Sloan Kettering Cancer Center (78) · Masonic Cancer Center, University of Minnesota (59) · Novartis Pharmaceuticals (55) · Institute of Hematology & Blood Diseases Hospital, China (42) · City of Hope Medical Center (40) · The First Affiliated Hospital of Soochow University (39) · Gruppo Italiano Malattie EMatologiche dell'Adulto (35) · Mayo Clinic (33) · St. Jude Children's Research Hospital (33) · H. Lee Moffitt Cancer Center and Research Institute (32) · National Heart, Lung, and Blood Institute (NHLBI) (30) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (28)
United States (2302) · China (395) · Germany (296) · France (293) · Italy (269) · Canada (225) · Spain (192) · United Kingdom (184) · Australia (139) · South Korea (110) · Netherlands (104) · Belgium (102) · Poland (85) · Israel (78) · Austria (76)
Jorge Cortes, MD (19) · Brenda Sandmaier (13) · Elias Jabbour, MD (13) · Farhad Ravandi-Kashani, MD (12) · Guillermo Garcia-Manero, MD (12) · Elias Jabbour (11) · Courtney DiNardo, MD (10)
PMID 41671463, PMID 32499241, PMID 34515338, PMID 35622074, PMID 23524640, PMID 34398557, PMID 23065508, PMID 28835440, PMID 29358183, PMID 30885996, PMID 33394722, PMID 23620574, PMID 27209293, PMID 29618479, PMID 30062662, PMID 33242441, PMID 36184192, PMID 21403127, PMID 22430088, PMID 25361995, PMID 26182309, PMID 28054442, PMID 29702001, PMID 31171508, PMID 34048072, PMID 34608724, PMID 35007144, PMID 35235189, PMID 35982483, PMID 40073835, PMID 41843779, PMID 17715389, PMID 18596230, PMID 18997171, PMID 19141862, PMID 19179301, PMID 19667400, PMID 19826119, PMID 21527516, PMID 21623761, PMID 21659356, PMID 22133778, PMID 22158386, PMID 22289993, PMID 23547837, PMID 23886836, PMID 24383844, PMID 24443277, PMID 24719405, PMID 24862638
P30CA015704 (60), U10CA031946 (32), 2023 (27), P30CA015083 (24), P30CA016672 (24), P30CA033572 (24), 2018 (23), U10CA032102 (23), P30CA006973 (22), P01CA018029 (21), 2015 (19), 2025 (19), 2008 (17), 2009 (17), 2016 (16)